Clinical Trial Update: A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma [Phase 2]

View source ↗

Summary

Amgen is conducting a Phase 2 dose-ranging trial of Rocatinlimab in moderate-to-severe asthma. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Asthma | Phase 2 | Status: ACTIVE_NOT_RECRUITING